scholarly journals Managing diabetes with inhaled insulin

2012 ◽  
Vol 3 (1) ◽  
pp. 51
Author(s):  
Lucy D Mastrandrea
Keyword(s):  
World Wide ◽  
Insulin Infusion ◽  
Insulin Administration ◽  
Efficacy And Safety ◽  
Inhaled Insulin ◽  
Pulmonary System ◽  
The Status ◽  
Microvascular And Macrovascular Complications ◽  
Alternate Routes ◽  
Continuous Insulin Infusion

The incidence of diabetes is increasing world-wide. Many individuals with diabetes require insulin to control their blood sugar and prevent both microvascular and macrovascular complications associated with this chronic disease. Current regimens involve delivery of subcutaneous insulin by injection or continuous insulin infusion. One area of research to advance diabetes care is aimed at developing alternate routes of insulin administration that will make daily management less invasive for patients. This review will focus on inhaled insulin, a novel formulation which takes advantage of drug delivery through the pulmonary system. The pharmacology, efficacy, and safety of inhaled insulin will be discussed. In addition, the status of inhaled insulin as a potential therapy for individuals with diabetes will be reviewed.

scholarly journals Managing diabetes with inhaled insulin

2012 ◽  
Vol 3 (1) ◽  
pp. 51-65
Author(s):  
Lucy D Mastrandrea
Keyword(s):  
World Wide ◽  
Insulin Infusion ◽  
Insulin Administration ◽  
Efficacy And Safety ◽  
Inhaled Insulin ◽  
Pulmonary System ◽  
The Status ◽  
Microvascular And Macrovascular Complications ◽  
Alternate Routes ◽  
Continuous Insulin Infusion

The incidence of diabetes is increasing world-wide. Many individuals with diabetes require insulin to control their blood sugar and prevent both microvascular and macrovascular complications associated with this chronic disease. Current regimens involve delivery of subcutaneous insulin by injection or continuous insulin infusion. One area of research to advance diabetes care is aimed at developing alternate routes of insulin administration that will make daily management less invasive for patients. This review will focus on inhaled insulin, a novel formulation which takes advantage of drug delivery through the pulmonary system. The pharmacology, efficacy, and safety of inhaled insulin will be discussed. In addition, the status of inhaled insulin as a potential therapy for individuals with diabetes will be reviewed.

Platelet function during continuous insulin infusion treatment in insulin-dependent diabetic patients

Diabetes ◽  
1985 ◽  
Vol 34 (11) ◽  
pp. 1127-1133 ◽  
Author(s):  
R. K. Mayfield ◽  
P. V. Halushka ◽  
H. J. Wohltmann ◽  
M. Lopes-Virella ◽  
J. K. Chambers ◽  
...  
Keyword(s):  
Platelet Function ◽  
Insulin Infusion ◽  
Diabetic Patients ◽  
Insulin Dependent ◽  
Insulin Dependent Diabetic ◽  
Continuous Insulin Infusion

Role of gluconeogenesis in sustaining glucose production during hypoglycemia caused by continuous insulin infusion in conscious dogs

Diabetes ◽  
1988 ◽  
Vol 37 (6) ◽  
pp. 749-759 ◽  
Author(s):  
R. T. Frizzell ◽  
G. K. Hendrick ◽  
D. W. Biggers ◽  
D. B. Lacy ◽  
D. P. Donahue ◽  
...  
Keyword(s):  
Insulin Infusion ◽  
Glucose Production ◽  
Conscious Dogs ◽  
Continuous Insulin Infusion

Simplified Approach to Incorporating Glycemic Response Within a Continuous Insulin Infusion Algorithm to Improve the Incidence of Hypoglycemia in a Single Burn Center

2020 ◽  
Vol 41 (4) ◽  
pp. 791-795
Author(s):  
Hayden A Hendrix ◽  
Sai R Velamuri ◽  
Ibrahim Sultan-Ali ◽  
Faisal Arif ◽  
William L Hickerson ◽  
...  
Keyword(s):  
Insulin Infusion ◽  
Point Of Care ◽  
Glucose Monitoring ◽  
Burn Patients ◽  
Glycemic Response ◽  
Simplified Approach ◽  
Thermal Injuries ◽  
Continuous Insulin Infusion ◽  
Related Mortality

Abstract Attaining adequate glycemic control in burn patients has been shown to reduce infection-related mortality. Previous internal evaluation of continuous insulin infusion (CII) use revealed a hypoglycemia rate of 0.6% and an average time within goal glycemic range (70–149 mg/dl) of 13.8 h/day. A new algorithm, designed to adjust dosage based on glycemic response, underwent six iterations over 2 years before the final version was implemented. The purpose of this retrospective study was to assess the post-implementation performance of the newly developed CII algorithm. The current study was powered to detect a 50% reduction in hypoglycemic events, as compared to a pre-implementation historical control. The cohort was 62% male with a mean age of 54.5 ± 17.4. Sixty-five percent had thermal injuries with a median 23.5 (11–45) %TBSA. There were no differences in demographics between groups. Among the 20 records reviewed, 5239 point-of-care glucose values were assessed. Post-implementation, hypoglycemia rates were significantly lower (0.6% vs 0.2%; P < .001). There was no difference in median blood glucose between groups (149.9 vs 146.5 mg/dl; P = .56). Time spent within goal glycemic range was not significantly different (13.8 vs 14.7 h/day; P = 0.23). There were no differences in infection, length of stay, or survival. The consolidation, education, and implementation of a single, dynamic CII algorithm reduced the incidence of hypoglycemia. The authors expect that education and diligence with follow-up glucose monitoring will further improve time within goal glycemic range by preventing rebound hyperglycemia.

Sign in / Sign up

Export Citation Format

Share Document